Stocks / AMEX / Nasus Pharma Ltd.

Nasus Pharma Ltd.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: NSRX – AMEX

Animal Usage: Animal Testing

Our Opinion

Nasus Pharma Ltd. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in the following report that they exploit animals for product testing.

“To further assess the feasibility of intranasal atropine administration, an animal study was conducted in male Sprague Dawley (SD) rats. The study compared the PK profile of atropine following intranasal administration at doses of 3 mg and 9 mg (human-equivalent doses) to that of an IM dose equivalent to 1 mg of atropine in humans.” (Page 107) Read the full document

Company Description

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Company Website: https://www.nasuspharma.com

Contact: info@nasuspharma.com